Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032

Open access
Søndergaard, Jonas N, Nazarian, Ramin, Wang, Qi, Guo, Deliang, Hsueh, Teli, Mok, Stephen, Sazegar, Hooman, MacConaill, Laura E, Barretina, Jordi G, Kehoe, Sarah M, Attar, Narsis, von Euw, Erika, Zuckerman, Jonathan E, Chmielowski, Bartosz, Comin-Anduix, Begoña, Koya, Richard C, Mischel, Paul S, Lo, Roger S, Ribas, Antoni·2010·Journal of Translational Medicine

Abstract

Blocking oncogenic signaling induced by the BRAF V600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell lines with the BRAF V600E mutation. Seven out of 10 BRAF V600E mutant cell lines displayed sensitivity based on cell viability assays and three were resistant at concentrations up to 10 μM. Among the sensitive cell lines, four were highly sensitive with IC 50 values below 1 μM, and three were moderately sensitive with IC 50 values between 1 and 10 μM. There was evidence of MAPK pathway inhibition and cell cycle arrest in both sensitive and resistant cell lines. Genomic analysis by sequencing, genotyping of close to 400 oncogeninc mutations by mass spectrometry, and SNP arrays demonstrated no major differences in BRAF locus amplification or in other oncogenic events between sensitive and resistant cell lines. However, metabolic tracer uptake studies demonstrated that sensitive cell lines had a more profound inhibition of FDG uptake upon exposure to PLX4032 than resistant cell lines. In conclusion, BRAF V600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-8-39

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 228

Metadata

Authors
Søndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J. G., Kehoe, S. M., Attar, N., von Euw, E., Zuckerman, J. E., Chmielowski, B., Comin-Anduix, B., Koya, R. C., Mischel, P. S., Lo, R. S., & Ribas, A.
Venue
Journal of Translational Medicine
Published
2010-04-20
Volume
8
Issue
1
Pages
39-39
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2108537717
Cited by
228
References
4
FWCI
9.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. https://app.cochat.ai/papers/10.1186/1479-5876-8-39
The paper
Søndergaard, J. N., Nazarian, R., Wang, Q., Guo, D., Hsueh, T., Mok, S., Sazegar, H., MacConaill, L. E., Barretina, J. G., Kehoe, S. M., Attar, N., von Euw, E., Zuckerman, J. E., Chmielowski, B., Comin-Anduix, B., Koya, R. C., Mischel, P. S., Lo, R. S., & Ribas, A. (2010). Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-8-39

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.